

Consultation workshop | Preparedness for emerging diseases

Agenda

29.09.2016 • IMI Stakeholder Forum

Hotel Crowne Plaza Le Palace • Rue Gineste 3 • Brussels, Belgium

8:30 – 09:00

Registration & networking breakfast

09:00 – 9:30

Opening session

Plenary | Ballroom

Pierre Meulien, IMI Executive Director

9:30

Introduction to the consultation workshop

Exploration room

Angela Wittelsberger, Scientific Officer, IMI

9:35

Setting the scene

Exploration room

09:35 – 9:50

Threats and risks at global level

Marie-Paule Kieny, Assistant Director-General - Health Systems and Innovation, World Health Organization (WHO)

9:50 – 10:05

Current and Future Threats for Europe

Piotr Kramarz, Deputy Chief Scientist, European Centre for Disease Prevention and Control (ECDC)

10:05 – 10:20

The European Commission: current research and innovation strategy and actions

Line Matthiessen, Head of Unit, Fighting infectious diseases and advancing public health, DG Research & Innovation, European Commission

10:20 – 10:35

Coalition for Epidemic Preparedness Innovations (CEPI)

John-Arne Røttingen, Director of the Division of Infectious Disease Control, Norwegian Institute of Public Health; CEPI

10:35 – 10:50

Questions & Answers

10:50 – 11:20

Coffee break

11:20

Key determinants of biopreparedness I: diagnostic platforms & early detection

Exploration room

11:20 – 11:30

The role of diagnostics in biopreparedness

Mark Miller, Chief Medical Officer, BioMérieux

11:30 – 11:40

COMPARE - A global platform for the sequence-based rapid identification of pathogens

Frank Møller Aarestrup, Professor, Head of Research Group, Technical University of Denmark; COMPARE project

11:40 – 12:30

Panel discussion on early detection and diagnostics

Frank Møller Aarestrup, COMPARE project

Marie-Paule Kieny, WHO

Piotr Kramarz, ECDC

Mark Miller, BioMérieux

Moderated by Evelyn Depoortere, European Commission

12:30 – 13:30

Lunch break

13:30

Key determinants of biopreparedness II: treatment and vaccine development

Exploration room

13:30 – 13:40

Perspectives on anti-infective therapeutic agents as part of a biopreparedness strategy

Kenny Simmen, Vice President, Innovation, Janssen Infectious Diseases & Vaccines

13:40 – 13:50

The industry perspective on vaccines: the way forward

Jean Lang, Associate Vice President, R&D Policy Head, Sanofi Pasteur

13:50 – 14:00

EDCTP perspective on biopreparedness and related capacity development in Africa

Michael Makanga, Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP)

14:00 – 14:45

Panel discussion: capacity and facilitating opportunities for vaccines and drug development

Jean Christophe Audonnet, Senior Director, Research Strategy & Key Alliances EU-Asia, R&D External Innovation, Meril; ZAPI project

Philippe Denoel, Director, External R&D, GlaxoSmithKline Biologicals

Herman Goossens, Director of the Department of Clinical Pathology of the University Hospital, Professor of Microbiology at the University of Antwerp

Michael Makanga, EDCTP

Kenny Simmen, Janssen

Moderated by Jean Lang, Sanofi Pasteur

14:45 – 15:00

Coffee break

15:00

The legal and regulatory framework for licensure of medical countermeasures during public health emergencies

Exploration room

Marco Cavaleri, Head of Anti-infective and Vaccines, European Medicines Agency (EMA)

15:15 – 16:00

Discussion: How can public and private players help? What role for public-private partnerships?

Exploration room

Marco Cavaleri, EMA

Marie-Paule Kieny, WHO

Jean Lang, Sanofi Pasteur

John-Arne Røttingen, Norwegian Institute of Public Health; CEPI

Angela Wittelsberger, IMI

Moderated by Line Matthiessen, European Commission

16:00 – 17:00

IMI Stakeholder Forum concluding remarks

Plenary | Ballroom

Feedback from *rapporteurs* of parallel sessions

Conclusions by Maria Beatriz Da Silva Lima, Professor of Pharmacology and Pharmacotoxicology, Lisbon University, Chair of the IMI Scientific Committee